Overview

LD-FUD for Highly Aggressive Gastric Cancer

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
A subtype of gastric adenocarcinoma with extensive bone marrow metastasis and DIC has been described. Few patients have been treated properly due to the lack of clinical trials. We designed this phase II study to explore a feasible regimen for this kind of highly aggressive gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Treatments:
Docetaxel
Fluorouracil